Juan Ramos, MD
Hematology & Oncology · Miami, FLNPI 1215963145
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,708 of the $14,338 with a category attached, or 95.6%. Acrotech Biopharma Inc. accounts for 95.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $9,123 and has fallen 98.4% since, to $145 in 2025.
Across 22 payments — averaging $651.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acrotech Biopharma Inc.$14K
- Kyowa Kirin, Inc.$145
- Jazz Pharmaceuticals Inc.$130
- Stemline Therapeutics Inc.$123
- TG Therapeutics, Inc.$120
- Genetix Biotherapeutics Inc$56
- plus $56 from 4 others
Across 5 payments — averaging $3090.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acrotech Biopharma Inc.$15K
What the payments were for
- Consulting fees$13,70896%
- Food & beverage$6304%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acrotech Biopharma Inc. | 12 | $13,708 |
| Kyowa Kirin, Inc. | 2 | $145 |
| Jazz Pharmaceuticals Inc. | 1 | $130 |
| Stemline Therapeutics Inc. | 1 | $123 |
| TG Therapeutics, Inc. | 1 | $120 |
| Genetix Biotherapeutics Inc | 1 | $56 |
| AstraZeneca | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Seagen Inc. | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,338 in reported general payments places this provider in the 65th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 31 | $232 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $103 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.